Amyris Inc. (NASDAQ:AMRS) major shareholder (Mauritius) Pte Ltd Maxwell sold 648,342 shares of Amyris stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $0.81, for a total value of $525,157.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

(Mauritius) Pte Ltd Maxwell also recently made the following trade(s):

  • On Friday, November 11th, (Mauritius) Pte Ltd Maxwell sold 427,904 shares of Amyris stock. The stock was sold at an average price of $0.81, for a total value of $346,602.24.
  • On Tuesday, November 8th, (Mauritius) Pte Ltd Maxwell sold 333,811 shares of Amyris stock. The stock was sold at an average price of $0.82, for a total value of $273,725.02.
  • On Friday, November 4th, (Mauritius) Pte Ltd Maxwell sold 2,611,233 shares of Amyris stock. The stock was sold at an average price of $0.89, for a total value of $2,323,997.37.
  • On Monday, October 17th, (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of Amyris stock. The stock was sold at an average price of $0.83, for a total value of $1,909,000.00.

Amyris Inc. (NASDAQ:AMRS) traded down 4.125% during midday trading on Thursday, reaching $0.774. The company’s stock had a trading volume of 2,654,427 shares. The firm has a 50 day moving average price of $0.83 and a 200-day moving average price of $0.57. Amyris Inc. has a 52 week low of $0.31 and a 52 week high of $1.81. The firm’s market cap is $203.57 billion.

Amyris (NASDAQ:AMRS) last issued its earnings results on Wednesday, November 2nd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.01. The firm had revenue of $26.50 million for the quarter, compared to the consensus estimate of $33.61 million. The business’s revenue for the quarter was up 208.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.23) earnings per share. On average, analysts forecast that Amyris Inc. will post ($0.25) earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research downgraded Amyris from a “hold” rating to a “sell” rating in a research report on Monday, November 7th. Singular Research reaffirmed a “buy” rating and set a $2.80 price objective on shares of Amyris in a report on Wednesday, September 28th.

Several large investors have recently modified their holdings of the stock. KBC Group NV boosted its stake in shares of Amyris by 330.1% in the third quarter. KBC Group NV now owns 329,101 shares of the company’s stock worth $191,000 after buying an additional 252,589 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Amyris during the first quarter worth about $269,000. Finally, Vanguard Group Inc. boosted its stake in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares during the last quarter. 35.75% of the stock is currently owned by institutional investors.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.